Gastrointestinal(GI)cancers,including colorectal cancer,pancreatic cancer,liver cancer and gastric cancer,are severe social burdens due to high incidence and mortality rates.Bromodomain and extra-terminal(BET)proteins...Gastrointestinal(GI)cancers,including colorectal cancer,pancreatic cancer,liver cancer and gastric cancer,are severe social burdens due to high incidence and mortality rates.Bromodomain and extra-terminal(BET)proteins are epigenetic readers consisting of four conserved members(BRD2,BRD3,BRD4 and BRDT).BET family perform pivotal roles in tumorigenesis through transcriptional regulation,thereby emerging as potential therapeutic targets.BET inhibitors,disrupting the interaction between BET proteins and acetylated lysines,have been reported to suppress tumor initiation and progression in most of GI cancers.In this review,we will demonstrate how BET proteins participate in the GI cancers progression and highlight the therapeutic potential of targeting BET proteins for GI cancers treatment.展开更多
基金Fellowship of the China Postdoctoral Science Foundation,No.2020M682594,and No.2021T140748.
文摘Gastrointestinal(GI)cancers,including colorectal cancer,pancreatic cancer,liver cancer and gastric cancer,are severe social burdens due to high incidence and mortality rates.Bromodomain and extra-terminal(BET)proteins are epigenetic readers consisting of four conserved members(BRD2,BRD3,BRD4 and BRDT).BET family perform pivotal roles in tumorigenesis through transcriptional regulation,thereby emerging as potential therapeutic targets.BET inhibitors,disrupting the interaction between BET proteins and acetylated lysines,have been reported to suppress tumor initiation and progression in most of GI cancers.In this review,we will demonstrate how BET proteins participate in the GI cancers progression and highlight the therapeutic potential of targeting BET proteins for GI cancers treatment.
